November 10, 2021 07:26 AM ESTUpdated November 11, 03:24 PM
Discovery

Lig­and to split in half, spin­ning Om­niAb plat­form in­to its own com­pa­ny

Nicole DeFeudis

Editor

It’s been six years since Lig­and Phar­ma­ceu­ti­cals plumped down $178 mil­lion for OMT and its an­ti­body dis­cov­ery plat­form Om­niAb. Now, with a slate of big …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times